ROIV · Roivant Sciences Ltd. · Webcasts, Transcripts & Audio
$39.57
+0.04 (+0.10%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q2 2027 earnings call transcript
Market Cap
$28.64B
Shares
724.56M
Volume · Nov 16
1.73M
Avg daily vol (3M)
8.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Roivant Sciences Ltd. Webcasts
Earnings calls, investor updates, investor days and conferences for Roivant Sciences Ltd. (ROIV), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Capital Markets Day
Investor event
2026-12-09
Roivant Sciences Ltd. (ROIV) December 9, 2026 Capital Markets Day
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Roivant Sciences Ltd. (ROIV) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY27 · Q2
2026-11-09
Roivant Sciences Ltd. (ROIV) Q2 2027 Earnings Call Transcript
Confident tone
IMVG-1402 rheumatoid arthritis results
Mosley-Sigawat PHILD program
NIU clinical program
Revenue
$35.12M
▲ 2135.6% YoY Diluted EPS
$-0.27
Gross margin
90.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-22
Roivant Sciences Ltd. (ROIV) September 22, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-10
Roivant Sciences Ltd. (ROIV) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Roivant Sciences Ltd. (ROIV) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY27 · Q1
2026-08-06
Roivant Sciences Ltd. (ROIV) Q1 2027 Earnings Call Transcript
Confident tone
Pipeline catalysts and second-half data
IMVT-1402 FcRn program (Graves, MG, CIDP)
Cutaneous sarcoidosis phase 3
Revenue
$1.44M
▼ 33.5% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Roivant Sciences Ltd. (ROIV) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Roivant Sciences Ltd. (ROIV) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-29
Roivant Sciences Ltd. (ROIV) May 29, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q4
2026-05-20
Roivant Sciences Ltd. (ROIV) Q4 2026 Earnings Call Transcript
Confident tone
Period 2 randomized withdrawal readout
Mosliciguat PH-ILD Phase 2B
Commercial launch execution
Revenue
$2.52M*
▼ 66.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-05-13
Roivant Sciences Ltd. (ROIV) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-02-06
Roivant Sciences Ltd. (ROIV) Q3 2026 Earnings Call Transcript
Confident tone
BREPO Phase 2 data in cutaneous sarcoidosis
Competitive landscape vs Argenix in Graves/TED
Graves' disease program and launch readiness
Revenue
$2.00M
▼ 77.8% YoY Diluted EPS
$-0.38
▼ 265.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2025-11-10
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Confident tone
Batoclimab/1402 in Graves' disease
TED and competitive landscape
Late-stage pipeline and upcoming readouts
Revenue
$1.57M
▼ 64.9% YoY Diluted EPS
$-0.17
Gross margin
92.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-08-11
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call
Revenue
$2.17M
▼ 72.8% YoY Diluted EPS
$-0.33
▼ 375% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-05-29
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Confident tone
Batoclimab / TED program failure
Period 2 randomized withdrawal and placebo
1402 / DGTRA open-label data
Revenue
$7.57M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-02-10
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Confident tone
Brepocitinib registrational programs and upcoming milestones
Pipeline catalysts and 2026 catalysts
Graves' disease launch and competitive landscape
Revenue
$9.02M
▼ 42.1% YoY Diluted EPS
$0.23
▼ 96.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2024-11-12
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Confident tone
IMVT-1402 across multiple indications
Graves' disease and batoclimab/1402 strategy
Brepocitinib VALOR data in dermatomyositis
Revenue
$4.47M
▲ 22.7% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-08-08
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Revenue
$7.99M
▼ 63.1% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-05-30
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call
Revenue
−$8.12M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-02-13
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Confident tone
Indication selection strategy for brepasitinib
Catalysts and milestones in 2025
Pipeline breadth and BD activity
Revenue
$15.56M
▼ 8.7% YoY Diluted EPS
$6.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2023-11-13
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Revenue
$3.65M
▼ 70.9% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-08-14
Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript
Revenue
$21.62M
▲ 400.7% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-06-28
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
Revenue
−$2.37M*
▼ 125.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-02-01
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Revenue
$17.05M
▼ 29.9% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2022-11-14
Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
Revenue
$12.53M
▼ 10.4% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-08-15
Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript
Revenue
$4.32M
▼ 44.2% YoY Diluted EPS
$-0.48
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-06-28
Roivant Sciences Ltd. (ROIV) Q4 2022 Earnings Call Transcript
Revenue
$9.22M*
▼ 39.1% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-02-14
Roivant Sciences Ltd. (ROIV) Q3 2022 Earnings Call Transcript
Revenue
$24.34M
▲ 323.3% YoY Diluted EPS
$-0.41
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2021-11-15
Roivant Sciences Ltd. (ROIV) Q2 2022 Earnings Call Transcript
Revenue
$13.99M
▲ 957.2% YoY Diluted EPS
$-0.32
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-09-21
Roivant Sciences Ltd. (ROIV) Q1 2022 Earnings Call Transcript
Revenue
$7.74M
▲ 390.8% YoY Diluted EPS
$-0.13
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2020-09-30
Date not confirmed
Roivant Sciences Ltd. (ROIV) Q2 2021 Earnings Call Transcript
Revenue
$1.32M
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–32 of 32 webcasts
Key facts
CIK
1635088
CUSIP
G76279101
13F (30d)
387 filings
351 filers
Visit website
Investor relations